Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.

Market Cap 21.38B 3.16B 2.73B 2.52B 2.36B 4.4B 301B 4.48B 29.84B 11.58B 146B 11.85B 11.59B 506B P/E ratio 2026 *
163x
P/E ratio 2027 * 152x
Enterprise value 21.38B 3.16B 2.73B 2.52B 2.36B 4.4B 301B 4.48B 29.84B 11.58B 146B 11.85B 11.59B 506B EV / Sales 2026 *
28x
EV / Sales 2027 * 21.5x
Free-Float
64.03%
Yield 2026 *
-
Yield 2027 * -
05-19 Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. Approves Cash Dividend for 2025 CI
04-23 Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-21 Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. announced that it expects to receive CNY 300 million in funding CI
03-31 Tranche Update on Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.'s Equity Buyback Plan announced on June 24, 2025. CI
03-01 Hainan Lingqing Digital Pharmaceutical Technology Co., Ltd. announced that it has received CNY 450 million in funding from Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. CI
02-28 Kemai Biotech Co., Ltd. announced that it has received funding from Jiangsu Hualan New Pharmaceutical Material Co.,Ltd., Wuxi Capital Group Co.,Ltd, XtalPi Holdings Limited CI
01-20 Hainan Lingqing Digital Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 450 million in funding from Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. CI
01-08 Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. entered into a Share Transfer Agreement to acquire 35% stake in Ningbo Guangfeng Capsule Co., Ltd. from Ningbo Sprague Biotechnology Co., Ltd. for CNY 8.5 million. CI
01-05 Tranche Update on Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.'s Equity Buyback Plan announced on June 24, 2025. CI
22/10/25 Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
09/10/25 Tranche Update on Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.'s Equity Buyback Plan announced on June 24, 2025. CI
26/08/25 Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
24/06/25 Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. announces an Equity Buyback for CNY 200 million worth of its shares. CI
1 day+5.72%
1 week+2.52%
Current month+4.26%
1 month+34.80%
3 months+49.80%
6 months+168.11%
Current year+154.99%
1 week 113.96
Extreme 113.96
130.86
1 month 97
Extreme 97
132.55
Current year 47.05
Extreme 47.05
132.55
1 year 23.12
Extreme 23.1154
132.55
3 years 13.17
Extreme 13.1692
132.55
5 years 13.17
Extreme 13.1692
132.55
10 years 13.17
Extreme 13.1692
132.55
Manager TitleAgeSince
Chief Executive Officer 44 15/10/2009
Director of Finance/CFO 53 15/06/2019
Corporate Officer/Principal 63 15/10/2009
Director TitleAgeSince
Director/Board Member 69 15/10/2009
Chairman 44 21/03/2022
Director/Board Member 63 15/10/2018
Date Insider Type Main position Quantity % Market Cap.
04-19Buy

Chief Executive Officer

100 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+5.72%+2.52%+449.79%+422.81% 2.99B
+0.09%+1.06%+15.71%+17.43% 26.84B
+1.01%+0.82%-1.68%+16.68% 25.05B
+0.43%-0.53%+100.43%+126.40% 6.82B
+0.35%-3.01%-2.08% - 5.92B
+1.53%-0.63%+2.03%+24.04% 5.77B
-0.30%-4.71%+17.81%+85.56% 5.1B
+1.59%+0.74%+23.09%+95.19% 3.49B
+0.81%+2.73%+24.42%+57.30% 3.25B
-2.93%-0.55%+73.75%+28.11% 1.79B
Average +0.79%-0.40%+70.33%+97.06% 8.7B
Weighted average by Cap. +0.68%+0.06%+32.06%+51.21%

Financials

2026 *2027 *
Net sales 763M 113M 97.47M 89.82M 84.18M 157M 10.75B 160M 1.07B 413M 5.2B 423M 414M 18.06B 995M 147M 127M 117M 110M 205M 14.01B 209M 1.39B 539M 6.77B 552M 540M 23.54B
Net income 131M 19.41M 16.79M 15.47M 14.5M 27.08M 1.85B 27.57M 183M 71.2M 895M 72.86M 71.28M 3.11B 141M 20.78M 17.98M 16.57M 15.53M 29M 1.98B 29.53M 197M 76.26M 959M 78.04M 76.35M 3.33B
Net Debt - -
Logo Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.
Jiangsu Hualan New Pharmaceutical Material Co Ltd is a China-based company primarily engaged in the research, development, production and sales of packaging materials for injectable pharmaceuticals that come into direct contact with the drug. The Company’s main products include various types of coated rubber stoppers and conventional rubber stoppers. The Company also produces rubber components for pen syringes (cassette vials), assemblies for plastic infusion containers, silicone rubber products, medical devices, and accessories. The Company's pharmaceutical rubber stoppers are used to encapsulate various types of injectable drugs, vaccines, biological agents, antibiotics, infusions, blood collection containers, and anti-tumor drugs. The Company distributes its products within the domestic market and to overseas markets.
Employees
945
Date Price Change Volume
09/06/26 130.30 ¥ +5.72% 3,643,050
08/06/26 123.25 ¥ +0.20% 3,953,790
05/06/26 123.00 ¥ -1.28% 2,905,920
04/06/26 124.60 ¥ -3.40% 3,129,707
03/06/26 128.98 ¥ +11.19% 6,026,679
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
130.30CNY
Average target price
88.47CNY
Spread / Average Target
-32.10%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 301093 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW